A “prescription” to sit less and move more is the optimal first treatment choice for reducing mild to moderately elevated blood pressure and blood cholesterol in otherwise healthy… read more.
A new study led by researchers at Washington State University has identified a protein that could be the key to improving treatment outcomes after a heart attack. Published… read more.
The FDA is alerting health care providers to no longer implant end-stage heart failure patients with Medtronic’s Heartware Ventricular Assist Device (HVAD) System due to a growing body… read more.
Researchers at the Karolinska Institutet, University of Oxford and University of Copenhagen have shown that elevated levels of lipids known as ceramides can be associated with a ten-fold… read more.
Edwards Lifesciences announced the results of a real-world study comparing outcomes for patients with bicuspid aortic stenosis (AS) who were treated with SAPIEN 3 and SAPIEN 3 Ultra… read more.
Article by Bruce Sylvester. Vaping by teens and adults appears to be related to an increase in the likelihood of developing asthma and experiencing asthma attacks, researchers reported… read more.
A meta-analysis of 14 air pollution studies from around the world found that exposure to high levels of air pollutants during childhood increases the likelihood of high blood… read more.
Article written by Bruce Sylvester Patients at high risk for cardiovascular disease (CVD) – or who already have established cardiovascular disease and elevated plasma triglycerides — who use… read more.
Exclusively using (or “vaping”) e-cigarettes can help people quit smoking, but many people using e-cigarettes to quit smoking continue to smoke cigarettes.
Amarin Corporation announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a Great Britain Marketing Authorisation for Vazkepa (icosapent ethyl) as a treatment to reduce… read more.
Article written by Bruce Sylvester. E-cigarettes delivering cigarette-like levels of nicotine can reduce smoking and exposure to the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, also known as NNAL.
FibroGen, Inc. has provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase III program for the treatment of anemia of chronic… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
